Health
MASH may require personalized treatment as distinct disease subtypes emerge
Headline as filed by Medical Xpress.
Compare coverage — 1 report
| Publisher | Headline | Summary | Published | Detected | Delay | Source | Status |
|---|---|---|---|---|---|---|---|
| Medical Xpress | MASH may require personalized treatment as distinct disease subtypes emerge |
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease, affecting an estimated 38% of adults worldwide. Its progressive form, MASH, is characterized |
0m | medicalxpress.com | First |
Headlines and summaries belong to the publisher named beside them. “Published” is what their feed stated; “detected” is when PageNews first held the report. Delay is measured from the earliest report on this event and describes timing only.
Reader comments
Comments are written by readers. PageNews does not check them and does not stand behind them, and a name here is a name someone typed, not a person we have identified.
Nobody has commented on this story yet.